Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1YA-101[1] YA-101---[1] 17 💬
2YAM80----[1] 2 💬
3Yarrowia lipolytica lipase----[1] 298 💬
4YCJ-01 Full Spectrum cannbis Extract----[1] 158 💬
5Yeast[1] Yeast[1] Dried yeast 💬 --[2] 97, 113 💬
6Yellow fever vaccine[1] Yellow fever vaccine[1] Yellow fever vaccine 💬 --[8] 40, 44, 46, 50, 51, 52, 53, 107 💬
7Yellow Fever vaccine (17D)[1] Yellow fever vaccine[1] Yellow fever vaccine 💬 --[8] 40, 44, 46, 50, 51, 52, 53, 107 💬
8Yi Qi Yang Yin Decoction----[1] 53 💬
9Yiqi Yangyin Formula----[1] 53 💬
10Yisaipu[1] Yisaipu---[2] 46, 271 💬
11Yisaipu®[1] Yisaipu---[1] 271 💬
12YISAIPU® ( An etanercept biosimilar)[2] Etanercept,
Yisaipu		[1] Etanercept 💬 [2] LTA,
TNF 💬 		[66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬[1] 46 💬
13Yishen Daluo Yin granuls----[1] 13 💬
14YK012----[2] 49, 222 💬
15YKP509----[1] 144 💬
16YKST02----[2] 49, 66 💬
17YLB113----[1] 46 💬
18YM672----[1] 226 💬
19YM672 (IPD®)----[1] 226 💬
20Yohimbine[1] Yohimbine[2] Yohimbine hydrochloride ,
Yohimbine 💬 		[3] ADRA2A,
ADRA2B,
ADRA2C 💬 		[4] Hormone signaling, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬[1] 6 💬
21Yohimbine HCl[1] Yohimbine[2] Yohimbine hydrochloride ,
Yohimbine 💬 		[3] ADRA2A,
ADRA2B,
ADRA2C 💬 		[4] Hormone signaling, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬[1] 6 💬
22YOLT-101----[1] 79 💬
23YOLT-201----[1] 28 💬
24YOLT-202----[1] 231 💬
25YOLT-203----[1] 234 💬
26YONDELIS 0,25 mg polvo para concentrado para solución para perfusión----[1] 159 💬
27Yondelis 0.25 mg powder for concentrate for solution for infusion.----[1] 159 💬
28YONDELIS 1 mg polvo para concentrado para solución para perfusión----[1] 159 💬
29Yondelis 1 mg powder for concentrate for solution for infusion.----[1] 159 💬
30YRA-1909 high dose----[1] 46 💬
31YRA-1909 low dose----[1] 46 💬
32YRA-1909 mid dose----[1] 46 💬
33YTB323----[1] 49 💬
34YTS109----[1] 61 💬
35YTS109 cell----[6] 46, 48, 49, 51, 53, 61 💬
36YTS109 cell injection----[2] 49, 63 💬
37Yttrium-90 radiolabelled anti-CD66 antibody----[1] 28 💬
38Yttrium­90 radiolabelled anti­CD66----[1] 28 💬
39Yu-Shen formula----[1] 224 💬
40Yuxuebi tablet----[1] 271 💬